Thor Medical ASAFRA:8NN +1.71%26 ROA % is -8.83% as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,420 Biotechnology companies, Thor Medical ASA ranks better than 69.44% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Thor Medical ASA's annualizedNet Income for the quarter that ended in Dec. 2025 was €-4.78 Mil.
Thor Medical ASA's average Total Assets over the quarter that ended in Dec. 2025 was €54.13 Mil. Therefore, Thor Medical ASA's annualized ROA % for the quarter that ended in Dec. 2025 was -8.83%.
The historical rank and industry rank for Thor Medical ASA's ROA % or its related term are showing as below:
FRA:8NN'
s ROA % Range Over the Past 10 Years
Min: -153.2 Med: -43.04 Max: -10.33
Current: -10.33
During the past 13 years, Thor Medical ASA's highest ROA % was -10.33%. The lowest was -153.20%. And the median was -43.04%.
FRA:8NN's ROA % is ranked better than 69.44% of 1420
companies
in the Biotechnology industry
Industry Median: -32.87
vs FRA:8NN: -10.33
Thor Medical ASA (FRA:8NN) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Thor Medical ASA ROA % Related Terms
Thor Medical ASA ROA % Historical Data
* Premium members only.
The historical data trend for Thor Medical ASA's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Thor Medical ASA's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thor Medical ASA ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thor Medical ASA's ROA % distribution charts can be found below:
* The bar in red indicates where Thor Medical ASA's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Thor Medical ASA (FRA:8NN) has a ROA % of -8.83% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Thor Medical ASA and its competitors. According to the industry distribution chart, Thor Medical ASA ranks #434 out of 1420 companies in the Biotechnology industry, placing it in the top 30.6%.
Is Thor Medical ASA's ROA % too high?
Thor Medical ASA's current ROA % is -8.83%. Based on the distribution chart, Thor Medical ASA ranks #434 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Thor Medical ASA has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #434 out of 1420 companies for ROA %. This puts Thor Medical ASA in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Thor Medical ASA and its competitors. Thor Medical ASA's current ROA % is -8.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current ROA % of -8.83%. The current ROA % is -8.83%. Thor Medical ASA's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current ROA % is -8.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
26GF Score
Get the complete analysis for FRA:8NN
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8NN has been successfully added to your 
